We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HCA Holdings (HCA) Q2 Earnings: Uncertainty in the Cards?
Read MoreHide Full Article
HCA Holdings Inc. (HCA - Free Report) is set to report second-quarter 2016 results on Jul 28. Last quarter, the company posted earnings of $1.71 per share, which comfortably beat the Zacks Consensus Estimate by 22 cents.
We note that HCA surpassed the Zacks Consensus Estimate in the last four quarters, by an average of 9.04%.
Let’s see how things are shaping up for this quarter.
Factors at Play
HCA is expected to benefit from the growing admission rate and improving payer mix based on the prolonged implementation of the Affordable Care Act (Obamacare). Notably, in the first quarter, same facility Medicare admissions and equivalent admissions increased 0.8% and 2.1%, respectively.
Same facility Medicaid admissions and equivalent admissions also increased 1.4% and 4.3%, respectively, in this quarter.
Moreover, increasing investments in trauma, cardiology and rehab services are forecasted to drive growth in the long run.
Earnings Whispers
Our proven model does not conclusively show that HCA is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank of #1 (Strong Buy), #2 or at least #3 (Hold) for this to happen. That is not the case here as you will see below.
Zacks ESP: HCA currently has an Earnings ESP of -1.94%. This is because the Most Accurate estimate of $1.52 is lower than the Zacks Consensus Estimate of $1.55.
Zacks Rank: HCA has a Zacks Rank #3 (Hold) which increases the possibility of an earnings beat. However, when combined with a -1.94% ESP, it makes surprise prediction difficult.
Meanwhile, we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are a few stocks worth considering that, as per our model, have the right combination of elements to post an earnings beat this quarter:
Nektar Therapeutics (NKTR - Free Report) with an Earnings ESP of +50.00% and a Zacks Rank #1.
CytRx Corp. with an Earnings ESP of +15.00% and a Zacks Rank #1.
Zoetis Inc. (ZTS - Free Report) with an Earnings ESP of +2.27% and a Zacks Rank #2.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
HCA Holdings (HCA) Q2 Earnings: Uncertainty in the Cards?
HCA Holdings Inc. (HCA - Free Report) is set to report second-quarter 2016 results on Jul 28. Last quarter, the company posted earnings of $1.71 per share, which comfortably beat the Zacks Consensus Estimate by 22 cents.
We note that HCA surpassed the Zacks Consensus Estimate in the last four quarters, by an average of 9.04%.
Let’s see how things are shaping up for this quarter.
Factors at Play
HCA is expected to benefit from the growing admission rate and improving payer mix based on the prolonged implementation of the Affordable Care Act (Obamacare). Notably, in the first quarter, same facility Medicare admissions and equivalent admissions increased 0.8% and 2.1%, respectively.
Same facility Medicaid admissions and equivalent admissions also increased 1.4% and 4.3%, respectively, in this quarter.
HCA HOLDINGS Price and EPS Surprise
HCA HOLDINGS Price and EPS Surprise | HCA HOLDINGS Quote
Moreover, increasing investments in trauma, cardiology and rehab services are forecasted to drive growth in the long run.
Earnings Whispers
Our proven model does not conclusively show that HCA is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank of #1 (Strong Buy), #2 or at least #3 (Hold) for this to happen. That is not the case here as you will see below.
Zacks ESP: HCA currently has an Earnings ESP of -1.94%. This is because the Most Accurate estimate of $1.52 is lower than the Zacks Consensus Estimate of $1.55.
Zacks Rank: HCA has a Zacks Rank #3 (Hold) which increases the possibility of an earnings beat. However, when combined with a -1.94% ESP, it makes surprise prediction difficult.
Meanwhile, we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are a few stocks worth considering that, as per our model, have the right combination of elements to post an earnings beat this quarter:
Nektar Therapeutics (NKTR - Free Report) with an Earnings ESP of +50.00% and a Zacks Rank #1.
CytRx Corp. with an Earnings ESP of +15.00% and a Zacks Rank #1.
Zoetis Inc. (ZTS - Free Report) with an Earnings ESP of +2.27% and a Zacks Rank #2.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>